logo
logo
logo
logo
  • News
  • Approach
  • ESG
  • Portfolio
  • Team
  • Tech Investments
  • Contact

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021

17. September 2021
|In Portfolio News
|By eazee-designstudio

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021

17. September 2021
|In Portfolio News
|By eazee-designstudio

ImCheck Therapeutics today presented data at the ESMO Congress 2021 from its ongoing EVICTION Phase I/IIa clinical trial with its lead antibody ICT01showing anti-tumor immune responses, resulting in increased tumor infiltration and disease control in patients with a variety of relapsed/refractory solid tumors.

  • Prev
  • Next

© 2022 Wellington Partners. All rights reserved  |  Imprint  |  Privacy Policy | SFDR Disclosures | PRIIPS

Privacy Preference Center

Privacy Preferences